Global Antibody Drug Conjugates Market Report (2022 to 2031) – Featuring Bayer, Oxford BioTherapeutics and Genentech Among Others –

Global Antibody Drug Conjugates Market Report (2022 to 2031) – Featuring Bayer, Oxford BioTherapeutics and Genentech Among Others –

Global Antibody Drug Conjugates Market Report (2022 to 2031) – Featuring Bayer, Oxford BioTherapeutics and Genentech Among Others –

DUBLIN–(BUSINESS WIRE)–The “Antibody Drug Conjugates Global Market Report 2022: By Type, By Application, By Product, By Technology, By End-User” report has been added to’s offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global antibody drug conjugates market.

The global antibody drug conjugates market is expected to grow from $4.79 billion in 2021 to $5.90 billion in 2022 at a compound annual growth rate (CAGR) of 23.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $13.06 billion in 2026 at a CAGR of 22%.

Companies Mentioned

  • Bayer AG
  • Concortis Biotherapeutics
  • F.Hoffman-La Roche Ltd.
  • Immunomedics inc.
  • Oxford BioTherapeutics
  • Pfizer inc.
  • Seattle Genetics inc.
  • Takeda Pharmaceutical Company Limited
  • Abbvie inc.
  • Astellas Pharma/Agensys
  • Oxford BioTherapeutics
  • Agensys inc.
  • Antikor
  • Celldex Therapeutics
  • Genentech
  • Heidelberg Pharma
  • Immunomedics
  • Mersana Therapeutics
  • Millennium Pharmaceuticals
  • Progenics Pharmaceuticals
  • Roche Holding Ag
  • Synthon

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
  • Create regional and country strategies on the basis of local data and analysis
  • Identify growth segments for investment
  • Outperform competitors using forecast data and the drivers and trends shaping the market
  • Understand customers based on the latest market research findings
  • Benchmark performance against key competitors
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

The antibody-drug conjugates (ADCs) market consists of sales of antibody-drug conjugates (ADCs). Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent cytotoxic agents are attached using chemical linkers.

The main types of antibody drug conjugates are monoclonal antibodies, linker, drug or toxin and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different products include adcertis, kadcyla, others and involves various technologies such as immunogen technology, seattle genetics technology, immunomedics technology, others. It is used in blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumor, others and is implemented in hospital, clinics, others.

North America was the largest region in the antibody-drug conjugates (ADCs) market in 2021. Middle East is expected to be the largest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The antibody drug conjugates market is being driven by rising incidences of cancer globally. The major causes for most cancers include obesity, smoking, alcohol, improper eating habits. The Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. The rising incidences of cancer are expected to increase the demand for antibody drug conjugates driving market growth.

The challenges involved in the manufacturing of ADC’s is acting as a restraint on the antibody drug conjugates market. ADC manufacturing facilities require high capital investment and extensive specialized training for operators. ADC process development is complicated as it requires optimization of additional process steps that are not present in conventional monoclonal antibodies manufacturing such as the antibody-drug conjugation reaction and subsequent drug substance purification. Also, antibody drug conjugates must be manufactured in aseptic environments and operating personnel should be protected from the highly toxic drug compounds, thereby presenting operational difficulties.

Manufacturers of antibody drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, product knowledge and expand business.

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900